Ayşenur Şahin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ayşenur Şahin has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Aynur Özge
Department of Neurology, Mersin University School of Medicine, Mersin, Turkey
3 shared publications - Elif Ilgaz Aydınlar
Acıbadem University
3 shared publications - Pınar Yalınay Dikmen
Department of Neurology, Acibadem University School of Medicine, Türkiye
3 shared publications Aylin Bican Demir
Department of Neurology Uludag University School of Medicine Bursa Türkiye
2 shared publications- Bahar Taşdelen
Department of Biostatistics and Medical Informatics, Faculty of Medicine, Mersin University, Mersin, Türkiye
2 shared publications Deniz Tuncel Berktas
Department of Neurology Kahramanmaraş Sütçü Imam University Medical Faculty Kahramanmaraş Türkiye
2 shared publications
Latest Publications
- 6 November 2026
- Published by Taylor & Francis
- p. 99-104
Headache Disorders as Precursors to Sleep Dysregulation
Headache disorders and sleep disturbances exhibit a complex bidirectional interaction, whereby headache-related disruption of sleep architecture and sleep-related lowering of pain thresholds mutually exacerbate one another. A deeper understanding of this interplay is crucial for effective clinical management. This chapter explores headache disorders as potential precursors to a range of sleep disturbances. The chapter concludes by outlining contemporary, multidisciplinary management strategies, emphasizing the need for an integrated approach to optimize patient outcomes and prevent the chronicity arising from the interplay between both disorders.
- 6 November 2026
- Published by Taylor & Francis
- p. 99-104
Headache Disorders as Precursors to Sleep Dysregulation
Headache disorders and sleep disturbances exhibit a complex bidirectional interaction, whereby headache-related disruption of sleep architecture and sleep-related lowering of pain thresholds mutually exacerbate one another. A deeper understanding of this interplay is crucial for effective clinical management. This chapter explores headache disorders as potential precursors to a range of sleep disturbances. The chapter concludes by outlining contemporary, multidisciplinary management strategies, emphasizing the need for an integrated approach to optimize patient outcomes and prevent the chronicity arising from the interplay between both disorders.
- 22 July 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (11) , 2926-2934
Attitudes in Patients With Prodromal and Overt α ‐Synucleinopathy Toward Risk Disclosure: A Nationwide Registry
Background: Identification of individuals at increased risk for synucleinopathies is becoming more feasible with advances in biomarkers. However, the ethical and practical aspects of communicating disease risk remain unresolved, particularly across diagnostic groups and cultural contexts. Objectives: We aimed to evaluate attitudes toward disclosure of future synucleinopathy risk among individuals with isolated/idiopathic REM sleep behavior disorder (iRBD), as well as in individuals who developed Parkinson's disease (PD), or multiple system atrophy (MSA), in a large non‐Western registry. Methods: This nationwide survey study included participants from 28 movement disorders and sleep centers across Türkiye. Questionnaires assessing attitudes toward risk disclosure, additional testing, and clinical trial participation were administered face‐to‐face. Responses were analyzed using contingency tables and regression models. Results are reported following the Consensus‐Based Checklist for Reporting of Survey Studies (CROSS) guideline. Results: Among 1385 participants (1039 PD, 107 MSA, 239 iRBD), individuals with iRBD showed the highest support for risk disclosure (88.3%), exceeding PD (64.4%) and MSA (51.9%). Approval declined modestly (3–8%) when framed within the absence of disease‐modifying treatment. iRBD participants were more willing for additional testing but less willing to join clinical trials (31.8%) than PD (45.3%) or MSA (48%). MSA patients expressed the greatest concern about psychological impact. Male sex had more favorable views on disclosure and trial participation, while younger and better‐educated participants favored additional testing. Conclusions: Attitudes toward risk disclosure differ markedly across the synucleinopathy spectrum and demographic characteristics. Culturally informed and diagnosis‐specific disclosure strategies will be essential for trial recruitment and patient‐centered care.
- 22 July 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (11) , 2926-2934
Attitudes in Patients With Prodromal and Overt α ‐Synucleinopathy Toward Risk Disclosure: A Nationwide Registry
Background: Identification of individuals at increased risk for synucleinopathies is becoming more feasible with advances in biomarkers. However, the ethical and practical aspects of communicating disease risk remain unresolved, particularly across diagnostic groups and cultural contexts. Objectives: We aimed to evaluate attitudes toward disclosure of future synucleinopathy risk among individuals with isolated/idiopathic REM sleep behavior disorder (iRBD), as well as in individuals who developed Parkinson's disease (PD), or multiple system atrophy (MSA), in a large non‐Western registry. Methods: This nationwide survey study included participants from 28 movement disorders and sleep centers across Türkiye. Questionnaires assessing attitudes toward risk disclosure, additional testing, and clinical trial participation were administered face‐to‐face. Responses were analyzed using contingency tables and regression models. Results are reported following the Consensus‐Based Checklist for Reporting of Survey Studies (CROSS) guideline. Results: Among 1385 participants (1039 PD, 107 MSA, 239 iRBD), individuals with iRBD showed the highest support for risk disclosure (88.3%), exceeding PD (64.4%) and MSA (51.9%). Approval declined modestly (3–8%) when framed within the absence of disease‐modifying treatment. iRBD participants were more willing for additional testing but less willing to join clinical trials (31.8%) than PD (45.3%) or MSA (48%). MSA patients expressed the greatest concern about psychological impact. Male sex had more favorable views on disclosure and trial participation, while younger and better‐educated participants favored additional testing. Conclusions: Attitudes toward risk disclosure differ markedly across the synucleinopathy spectrum and demographic characteristics. Culturally informed and diagnosis‐specific disclosure strategies will be essential for trial recruitment and patient‐centered care.
- Open Access
- 23 June 2026
- Published by SAGE Publications in Cephalalgia Reports
- Vol. 9
Sex differences in cluster headache, treatment insights, and burden of disease in Türkiye: A multi-center cross-sectional study
Aim: There is a growing recognition of the need for sex-specific approaches in primary headache disorders. Research on sex differences in cluster headache (CH) is quite limited, and examining this data across different populations is crucial for understanding genetic and sociocultural differences. We aimed to investigate sex differences in clinical features, acute treatment responses, and the burden of CH in Türkiye. Methods: This multicenter cross-sectional study was conducted between January and June 2024 and involved patients with CH from tertiary healthcare centers, who met the International Classification of Headache Disorders (ICHD-3) criteria. Patients with cluster-like secondary headache conditions were not included. Sociodemographic data, clinical characteristics, acute treatment responses, and the burden of CH were assessed using a semi-structured questionnaire. Statistical comparisons were done between male and female patients. Results: A total of 318 patients (244 males, 76.7%), with a mean age of 45.0 ± 10.9 years, were included. Previous misdiagnosis rates were significantly higher in females (71.6%) compared to males (50.8%) ( p = 0.002). While the frequency and duration of cluster bouts were similar in both sexes, compared to males, females were more likely to experience headache attacks lasting longer than 2 h (44.3% vs. 60.8%; p < 0.013) and more frequently experience agitation during the attacks (66% vs. 79.7%; p = 0.025). The presence of autonomic symptoms also varied by sex; males reported higher rates of conjunctival injection (52.5% vs. 35.1%; p = 0.009) and facial sweating (37.3% vs. 17.6%; p = 0.002). Males showed a higher therapeutic benefit from subcutaneous sumatriptan (91.7% vs. 66.7%; p = 0.002). Both sexes reported a negative impact of CH on daily life in the previous year, with a mean of 18.3 days in males and 22.5 days in females. Conclusion: Several sex differences were observed in patients with CH: attack duration was longer, agitation during the attacks, and misdiagnosis were more frequent. On the other hand, autonomic features such as conjunctival injection and facial sweating tended to accompany CH attacks more often in males, who responded better to subcutaneous triptan than females. These findings highlight the necessity of investigating the underlying mechanisms of sex-specific differences in future research, as well as the careful consideration of these factors in diagnostic and treatment planning.
- 23 June 2026
- Published by SAGE Publications in Cephalalgia Reports
- Vol. 9
Open AccessSex differences in cluster headache, treatment insights, and burden of disease in Türkiye: A multi-center cross-sectional study
Aim: There is a growing recognition of the need for sex-specific approaches in primary headache disorders. Research on sex differences in cluster headache (CH) is quite limited, and examining this data across different populations is crucial for understanding genetic and sociocultural differences. We aimed to investigate sex differences in clinical features, acute treatment responses, and the burden of CH in Türkiye. Methods: This multicenter cross-sectional study was conducted between January and June 2024 and involved patients with CH from tertiary healthcare centers, who met the International Classification of Headache Disorders (ICHD-3) criteria. Patients with cluster-like secondary headache conditions were not included. Sociodemographic data, clinical characteristics, acute treatment responses, and the burden of CH were assessed using a semi-structured questionnaire. Statistical comparisons were done between male and female patients. Results: A total of 318 patients (244 males, 76.7%), with a mean age of 45.0 ± 10.9 years, were included. Previous misdiagnosis rates were significantly higher in females (71.6%) compared to males (50.8%) ( p = 0.002). While the frequency and duration of cluster bouts were similar in both sexes, compared to males, females were more likely to experience headache attacks lasting longer than 2 h (44.3% vs. 60.8%; p < 0.013) and more frequently experience agitation during the attacks (66% vs. 79.7%; p = 0.025). The presence of autonomic symptoms also varied by sex; males reported higher rates of conjunctival injection (52.5% vs. 35.1%; p = 0.009) and facial sweating (37.3% vs. 17.6%; p = 0.002). Males showed a higher therapeutic benefit from subcutaneous sumatriptan (91.7% vs. 66.7%; p = 0.002). Both sexes reported a negative impact of CH on daily life in the previous year, with a mean of 18.3 days in males and 22.5 days in females. Conclusion: Several sex differences were observed in patients with CH: attack duration was longer, agitation during the attacks, and misdiagnosis were more frequent. On the other hand, autonomic features such as conjunctival injection and facial sweating tended to accompany CH attacks more often in males, who responded better to subcutaneous triptan than females. These findings highlight the necessity of investigating the underlying mechanisms of sex-specific differences in future research, as well as the careful consideration of these factors in diagnostic and treatment planning.
- Open Access
- 1 June 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1792472
Clinical improvement of photophobia with galcanezumab in episodic and chronic migraine
Objective: This study aimed to evaluate changes in photophobia using the Turkish version of Utah Photophobia Symptom Impact Scale–12 (UPSIS-12) in patients with episodic (EM) and chronic migraine (CM) treated with galcanezumab, and to examine the relationship between photophobia, migraine outcomes, disability, and treatment response. Background: Photophobia is one of the most bothersome symptoms (MBS) of migraine and may persist during both ictal and interictal periods, leading to substantial impairment in daily functioning. Despite the clear clinical relevance of photophobia, the specific effects of galcanezumab, a CGRP monoclonal antibody, on photophobia have not yet been fully elucidated. Methods: This retrospective study, included patients with EM and CM treated with galcanezumab (240 mg loading dose followed by monthly 120 mg) for 3 months. Patients completed headache diaries and validated patient-reported outcome measures (PROMs) at baseline and monthly follow-up visits. Non-parametric tests, correlation analyses, and multivariable linear regression were performed. Results: A total of 77 patients were enrolled, of whom 47 (89.3% female; mean age 39.5 ± 10.6 years) completed all study visits and were included in the final analysis. Over the study period, monthly headache days (MHDs) decreased from a median of 15 to 4 days by month 3 ( p < 0.001), with 74.5% of patients classified as responders (≥50% reduction). UPSIS-12 scores declined significant (median 22.6%; p < 0.001). Although baseline UPSIS-12 scores were similar between responders and non-responders, responders demonstrated a notable reduction in ictal photophobia ( p = 0.010). Significant improvements were also observed in ictal phonophobia, osmophobia, and cutaneous allodynia, whereas interictal sensory symptoms remained largely unchanged. In addition, headache intensity, attack duration, acute medication use, disability (HIT-6, MIDAS), and comorbid depression (BDI) and anxiety (BAI) scores all improved. Treatment was well tolerated, with no serious adverse events reported. Conclusion: Galcanezumab was associated with clinically important reduction not only in migraine frequency, severity, disability, and psychological comorbidities, but also in ictal photophobia, highlighting its responsiveness to CGRP-targeted preventive therapy. These findings suggest that photophobia as a potentially modifiable outcome that warrants systematically evaluation in future studies, with larger cohorts and long-term follow-up.
- 1 June 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1792472
Open AccessClinical improvement of photophobia with galcanezumab in episodic and chronic migraine
Objective: This study aimed to evaluate changes in photophobia using the Turkish version of Utah Photophobia Symptom Impact Scale–12 (UPSIS-12) in patients with episodic (EM) and chronic migraine (CM) treated with galcanezumab, and to examine the relationship between photophobia, migraine outcomes, disability, and treatment response. Background: Photophobia is one of the most bothersome symptoms (MBS) of migraine and may persist during both ictal and interictal periods, leading to substantial impairment in daily functioning. Despite the clear clinical relevance of photophobia, the specific effects of galcanezumab, a CGRP monoclonal antibody, on photophobia have not yet been fully elucidated. Methods: This retrospective study, included patients with EM and CM treated with galcanezumab (240 mg loading dose followed by monthly 120 mg) for 3 months. Patients completed headache diaries and validated patient-reported outcome measures (PROMs) at baseline and monthly follow-up visits. Non-parametric tests, correlation analyses, and multivariable linear regression were performed. Results: A total of 77 patients were enrolled, of whom 47 (89.3% female; mean age 39.5 ± 10.6 years) completed all study visits and were included in the final analysis. Over the study period, monthly headache days (MHDs) decreased from a median of 15 to 4 days by month 3 ( p < 0.001), with 74.5% of patients classified as responders (≥50% reduction). UPSIS-12 scores declined significant (median 22.6%; p < 0.001). Although baseline UPSIS-12 scores were similar between responders and non-responders, responders demonstrated a notable reduction in ictal photophobia ( p = 0.010). Significant improvements were also observed in ictal phonophobia, osmophobia, and cutaneous allodynia, whereas interictal sensory symptoms remained largely unchanged. In addition, headache intensity, attack duration, acute medication use, disability (HIT-6, MIDAS), and comorbid depression (BDI) and anxiety (BAI) scores all improved. Treatment was well tolerated, with no serious adverse events reported. Conclusion: Galcanezumab was associated with clinically important reduction not only in migraine frequency, severity, disability, and psychological comorbidities, but also in ictal photophobia, highlighting its responsiveness to CGRP-targeted preventive therapy. These findings suggest that photophobia as a potentially modifiable outcome that warrants systematically evaluation in future studies, with larger cohorts and long-term follow-up.
- Open Access
- 1 April 2026
- Published by Baycinar Tibbi Yayincilik in Ağrı - The Journal of The Turkish Society of Algology
- Vol. 38 (2) , 83-95
Reliability and validity of Turkish version of Migraine-Specific Quality of Life v2.1 questionnaire
Background: This study aims to assess whether the Turkish version of the Migraine-Specific Quality of Life Questionnaire v2.1 (MSQ v2.1) is a reliable and valid tool for evaluating the impact of migraine on daily functioning and overall quality of life. Patients and Methods: This multi-center, descriptive, prospective study included a total of 182 migraine patients between December 2023 and May 2024. All patients were assessed at two visits with a four-week interval. The Turkish MSQ v2.1 was evaluated for comprehensibility, patient-physician reliability, internal consistency, test-retest reliability, and construct validity. Results: Of a total of 182 patients, 19 were male and 163 were female with a mean age of 40.8±12.2 (range, 18 to 73) years. Item comprehensibility was high, with 94 to 97.8% at Visit 1, and from 98.4 to 100% at Visit 2. A strong correlation was observed between self-administered and physician-administered MSQ v2.1 scores at Visit 1 (r = 0.916, p < 0.001). Internal consistency was excellent, with Cronbach’s alpha values of 0.932 at Visit 1 and 0.912 at Visit 2. Test-retest reliability was moderate (r = 0.468, p < 0.001). Construct validity was supported by strong correlations with the Headache Impact Test-6 (r = 0.751 at Visit 1 and r = 0.772 at Visit 2), monthly headache days (r = 0.453 and 0.553), and Numeric Rating Scale scores (r = 0.539 and 0.564), all with p < 0.001. Conclusion: The Turkish MSQ v2.1 is a reliable and valid tool for assessing health-related quality of life (HRQL) in migraine patients. It demonstrates excellent internal consistency, moderate test-retest reliability, and strong correlations with established measures of HRQL, headache severity, migraine frequency, and supporting its use in clinical practice and research.
- 1 April 2026
- Published by Baycinar Tibbi Yayincilik in Ağrı - The Journal of The Turkish Society of Algology
- Vol. 38 (2) , 83-95
Open AccessReliability and validity of Turkish version of Migraine-Specific Quality of Life v2.1 questionnaire
Background: This study aims to assess whether the Turkish version of the Migraine-Specific Quality of Life Questionnaire v2.1 (MSQ v2.1) is a reliable and valid tool for evaluating the impact of migraine on daily functioning and overall quality of life. Patients and Methods: This multi-center, descriptive, prospective study included a total of 182 migraine patients between December 2023 and May 2024. All patients were assessed at two visits with a four-week interval. The Turkish MSQ v2.1 was evaluated for comprehensibility, patient-physician reliability, internal consistency, test-retest reliability, and construct validity. Results: Of a total of 182 patients, 19 were male and 163 were female with a mean age of 40.8±12.2 (range, 18 to 73) years. Item comprehensibility was high, with 94 to 97.8% at Visit 1, and from 98.4 to 100% at Visit 2. A strong correlation was observed between self-administered and physician-administered MSQ v2.1 scores at Visit 1 (r = 0.916, p < 0.001). Internal consistency was excellent, with Cronbach’s alpha values of 0.932 at Visit 1 and 0.912 at Visit 2. Test-retest reliability was moderate (r = 0.468, p < 0.001). Construct validity was supported by strong correlations with the Headache Impact Test-6 (r = 0.751 at Visit 1 and r = 0.772 at Visit 2), monthly headache days (r = 0.453 and 0.553), and Numeric Rating Scale scores (r = 0.539 and 0.564), all with p < 0.001. Conclusion: The Turkish MSQ v2.1 is a reliable and valid tool for assessing health-related quality of life (HRQL) in migraine patients. It demonstrates excellent internal consistency, moderate test-retest reliability, and strong correlations with established measures of HRQL, headache severity, migraine frequency, and supporting its use in clinical practice and research.
- 27 January 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (2) , 205
Smoking and cluster headache: clinical, gender, and treatment insights from a cross-sectional cluster analysis
- 27 January 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (2) , 205
Smoking and cluster headache: clinical, gender, and treatment insights from a cross-sectional cluster analysis
- 1 April 2022
- Published by Elsevier in Sleep Medicine
- Vol. 94, 17-25
The REM-sleep-related characteristics of narcolepsy: a nation-wide multicenter study in Turkey, the REMCON study
- 1 April 2022
- Published by Elsevier in Sleep Medicine
- Vol. 94, 17-25
The REM-sleep-related characteristics of narcolepsy: a nation-wide multicenter study in Turkey, the REMCON study